Characterization of [3H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord

European Journal of Pharmacology

Volumn 520, Issue 1-3, 2005, Pages 70-76

  Lambeng, Nathalie ^a   Gillard, Michel ^a   Vertongen, Pascale ^b   Fuks, Bruno ^a   Chatelain, Pierre ^a  

^a UCB PHARMA   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Binding; Levetiracetam; Rat spinal cord; SV2A

Indexed keywords

(2 OXO 1 PYRROLIDINYL)BUTANAMIDE; 2 (2 OXO 4 PROPYLPYRROLIDIN 1 YL)BUTANAMIDE; 2 [4 (3 AZIDOPHENYL) 2 OXOPYRROLIDIN 1 YL]BUTANAMIDE; BEMEGRIDE; BRIVARACETAM; CHLORDIAZEPOXIDE; ETIRACETAM; LIGAND; NERVE PROTEIN; PENTETRAZOLE; PENTOBARBITAL; PYRROLIDINE DERIVATIVE; SYNAPTIC VESICLE PROTEIN 2A; TRITIUM; UCB 30889; UCB L 060; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING ASSAY; BINDING COMPETITION; BRAIN; CONTROLLED STUDY; DISEASE MODEL; DRUG BINDING SITE; DRUG PROTEIN BINDING; GRAY MATTER; NEUROPATHIC PAIN; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SPINAL CORD; WESTERN BLOTTING;

ANIMALS; ANTICONVULSANTS; AZIDES; BINDING SITES; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; KINETICS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PIRACETAM; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; SYNAPTIC VESICLES;

EID: 25444446397     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.07.029     Document Type: Article

References (34)

1. D. Ardid, Y. Lamberty, A. Alloui, M.A. Coudore-Civiale, H. Klitgaard, and A. Eschalier Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats Eur. J. Pharmacol. 473 2003 27 33
2. S.M. Bajjalieh, K. Peterson, R. Shinghal, and R.H. Scheller SV2, a brain synaptic vesicle protein homologous to bacterial transporters Science 257 1992 1271 1273
3. S.M. Bajjalieh, K. Peterson, M. Linial, and R.H. Scheller Brain contains two forms of synaptic vesicle protein 2 Proc. Natl. Acad. Sci. U. S. A. 90 1993 2150 2154
4. S.M. Bajjalieh, G.D. Frantz, J.M. Weimann, S.K. McConnell, and R.H. Scheller Differential expression of synaptic vesicle protein 2 (SV2) isoforms J. Neurosci. 14 1994 5223 5235
5. E. Ben-Menachem Levetiracetam: treatment in epilepsy Expert Opin. Pharmacother. 4 2003 2079 2088
6. S. Booj, M. Goldstein, R. Fischer-Colbrie, and A. Dahlstrom Calcitonin gene-related peptide and chromogranin A: presence and intra-axonal transport in lumbar motor neurons in the rat, a comparison with synaptic vesicle antigens in immunohistochemical studies Neuroscience 30 1989 479 501
7. R.E. Brooke, L. Atkinson, T.F. Batten, S.A. Deuchars, and J. Deuchars Association of potassium channel Kv3.4 subunits with pre- and post-synaptic structures in brainstem and spinal cord Neuroscience 126 2004 1001 1010
8. K. Buckley, and R.B. Kelly Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells J. Cell Biol. 100 1985 1284 1294
9. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
10. C. Courteix, A. Eschalier, and J. Lavarenne Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain Pain 53 1993 81 88
11. K.M. Crowder, J.M. Gunther, T.A. Jones, B.D. Hale, H.Z. Zhang, M.R. Peterson, R.H. Scheller, C. Chavkin, and S.M. Bajjalieh Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) Proc. Natl. Acad. Sci. U. S. A. 96 1999 15268 15273
12. M.B. Feany, S. Lee, R.H. Edwards, and K.M. Buckley The synaptic vesicle protein SV2 is a novel type of transmembrane transporter Cell 70 1992 861 867
13. B. Fuks, M. Gillard, P. Michel, B. Lynch, P. Vertongen, P. Leprince, H. Klitgaard, and P. Chatelain Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines Eur. J. Pharmacol. 478 2003 11 19
14. 3H]ucb 30889 to levetiracetam binding sites in rat brain Eur. J. Pharmacol. 478 2003 1 9
15. S.D. Gross, D.P. Hoffman, P.L. Fisette, P. Baas, and R.A. Anderson A phosphatidylinositol 4,5-bisphosphate-sensitive casein kinase I alpha associates with synaptic vesicles and phosphorylates a subset of vesicle proteins J. Cell Biol. 130 1995 711 724
16. C.A. Hovinga Levetiracetam: a novel antiepileptic drug Pharmacotherapy 21 2001 1375 1388
17. R. Janz, and T.C. Sudhof SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family Neuroscience 94 1999 1279 1290
18. R. Janz, K. Hofmann, and T.C. Sudhof SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles J. Neurosci. 18 1998 9269 9281
19. 2+ regulators in neurotransmitter release Neuron 24 1999 1003 1016
20. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of the bacteriophage T4 Nature (London) 227 1970 680 685
21. B.A. Lynch, N. Lambeng, K. Nocka, P. Kensel-Hammes, S.M. Bajjalieh, A. Matagne, and B. Fuks The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc. Natl. Acad. Sci. U. S. A. 101 2004 9861 9866
22. P.B. Molinoff, B.B. Wolfe, and G.A. Weiland Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes Life Sci. 29 1981 427 443
23. E.M. Nash, and K.S. Sangha Levetiracetam Am. J. Health-Syst. Pharm. 58 2001 1195 1199
24. P.G. Noakes, D. Chin, S.S. Kim, S. Liang, and W.D. Phillips Expression and localisation of dynamin and syntaxin during neural development and neuromuscular synapse formation J. Comp. Neurol. 410 1999 531 540
25. M. Noyer, M. Gillard, A. Matagne, J.P. Henichart, and E. Wulfert The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes Eur. J. Pharmacol. 286 1995 137 146
26. M.J. Price Levetiracetam in the treatment of neuropathic pain: three case studies Clin. J. Pain 20 2004 33 36
27. R.A. Pyle, A.E. Schivell, H. Hidaka, and S.M. Bajjalieh Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin J. Biol. Chem. 275 2000 17195 17200
28. M.H. Rashid, M. Inoue, S. Bakoshi, and H. Ueda Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice J. Pharmacol. Exp. Ther. 306 2003 709 717
29. A. Roosen, A. Schober, J. Strelau, M. Bottner, J. Faulhaber, G. Bendner, S.L. McIlwrath, H. Seller, H. Ehmke, G.R. Lewin, and K. Unsicker Lack of neurotrophin-4 causes selective structural and chemical deficits in sympathetic ganglia and their preganglionic innervation J. Neurosci. 21 2001 3073 3084
30. A.E. Schivell, R.H. Batchelor, and S.M. Bajjalieh Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin J. Biol. Chem. 271 1996 27770 27775
31. A.E. Schivell, S. Mochida, P. Kensel-Hammes, K.L. Custer, and S.M. Bajjalieh SV2A and SV2C contain a unique synaptotagmin-binding site Mol. Cell. Neurosci. 29 2005 56 64
32. T.W. Scranton, M. Iwata, and S.S. Carlson The SV2 protein of synaptic vesicles is a keratan sulfate proteoglycan J. Neurochem. 61 1993 29 44
33. M. Swerdlow Anticonvulsant drugs and chronic pain Clin. Neuropharmacol. 7 1984 51 82
34. J.Y. Wang, D.J. Wigston, H.D. Rees, A.I. Levey, and D.L. Falls LIM kinase 1 accumulates in presynaptic terminals during synapse maturation J. Comp. Neurol. 416 2000 319 334